AP37A - Antiparasitic agents and process of their preparation. - Google Patents

Antiparasitic agents and process of their preparation. Download PDF

Info

Publication number
AP37A
AP37A APAP/P/1986/000040A AP8600040A AP37A AP 37 A AP37 A AP 37A AP 8600040 A AP8600040 A AP 8600040A AP 37 A AP37 A AP 37A
Authority
AP
ARIPO
Prior art keywords
compound
double bond
alpha
formula
absent
Prior art date
Application number
APAP/P/1986/000040A
Other versions
AP8600040A0 (en
Inventor
Paul Stephen Gibson
Kelvin Scott Holdom
Alexander Crossan Goudie
John Desmond Bu'lock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27449680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP37(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB858518999A external-priority patent/GB8518999D0/en
Priority claimed from GB858520069A external-priority patent/GB8520069D0/en
Priority claimed from GB868610063A external-priority patent/GB8610063D0/en
Priority claimed from GB868610862A external-priority patent/GB8610862D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AP8600040A0 publication Critical patent/AP8600040A0/en
Application granted granted Critical
Publication of AP37A publication Critical patent/AP37A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Husbandry (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds having the formula wherein the broken line at the 22-23 position represents an optional double bond and wherein r1 is h or oh and the double bond is absent, or, the double bond is present and r1 is absent, r2 is an alpha-branched c3-c8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group; a c3-c8 cycloalkyl, c5-c8 cycloalkenyl or c5-c8 cycloalkylalkyl group, any of which may optionally be ubstituted by methylene or one or more c1-c4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may optionally be substituted by one or more c1-c4 alkyl groups or halo atoms; r3 is hydrogen or methyl; r4 is h or 4-(alpha-l-oleandrosyloxy, with the provision that when r2 is alkyl it is not isopropyl or sec-butyl; when r4 is h, r1 is h, and the double bond is absent, r2 is not mehtyl or ethyl; and when r4 is h, r1 is oh, and the double bond is absent, r2 is not 2-buten-2-yl, 2-pentene-2-yl or 4-methyl-2-pentene-2-yl. The compounds are broad spectrum antiparasitic agents having utility as anthelmintics, ectoparasiticides, insecticides and acaricides. The invention also provides a process for producing the novel avermectin and milbemycin derivatives by adding a carboxylic acid derivative thereof to a fermentation of an avermectin or milbemycin producing organism.

Description

ANTIPARASITIC AGENTS AND PROCESS FOR THEIR PREPARATION
DESCRIPTION
This invention relates to antiparasitic agents and in particular to compounds related to the avermectins and milbemycins but having a novel substituent group at the 25-position and to a process for their preparation.
The avermectins are a group of broad spectrum antiparasitic agents referred to previously as the C-076 compounds. They are produced by fermenting a strain of the microorganism Streptomyces avermitilis ATCC 31267, 31271 or 31272 under aerobic conditions in an aqueous nutrient medium containing inorganic salts and assimilable sources of carbon and nitrogen. The morphological and cultural properties of the strains ATCC 31267, 31271 and 31272 are described in detail in British Patent Specification no. 1573955 which also describes the isolation and the chemical structure of the eight individual components which make up the C-076 complex. The milbemycins are structurally related macrolide antibiotics lacking the sugar residues at the 13-position. They are produced by fermentation, for example as described in British Patent Specification no. 1390336 and European Patent Application publication no. 0170006.
We have now discovered that by adding certain specified carboxylic acids, or derivatives thereof, to the fermentation of an avermectin producing organism it is possible to obtain novel compounds, related to the avermectins but having an unnatural substituent group at the 25-position in place of the isopropyl or sec-butyl group which is normally present. The novel compounds are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasiticides, insecticides and acaricides.
Thus, according to one aspect of the invention there is provided a process for producing a novel avermectin derivative having an unnatural substituent group at the 25-position which comprises adding a carboxylic acid, or a salt, ester or amide thereof or oxidative precursor therefor, to a fermentation of an avermectin producing organism, and isolating ..the novej avermecpii.
* ·'’ ’’ ·’ ‘ . .J derivative. - 1AUGI986
P.0. Box 8O33t CA0UWAT ZftUMWl
PLC 414/417
Conventional chemical transformation reactions can be used to prepare further derivatives from these compounds. Thus, according to a further aspect of the invention there are provided compounds having the formula:
AP 0 0 0 0 3 7 wherein the broken line at the 22-23 position represents an optional double bond and wherein is H or OH and the double bond is absent, or, the double bond is present and is absent;
R is an alpha-branched C,-Co alkyl, alkenyl, alkynyl,
J 0 alkoxyalkyl or alkylthioalkyl group; a C^-Cg cycloalkylalkyl group wherein the alkyl group is an alpha-branched C.-C, alkyl group; a • 4 J
Cg-Cg cycloalkyl or C^-Cg cycloalkenyl group, either of which may optionally be substituted by methylene or one or more C^-C^ alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C^-C^ alkyl groups or halo atoms;
R^ is hydrogen or methyl;
R is H or a 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group of the formula:
with the proviso that when R is alkyl it is not isopropyl or 4 . 1 sec-butyl; when R is H, R is H, and the double bond is absent,
4 1
R is not methyl or ethyl; and when R is H, R is OH, and the double bond is absent, R is not 2-buten-2-yl, 2-penten-2-yl or
4-methyl-2-penten-2-yl.
In the above definition, alkyl groups containing 3 or more carbon atoms may be straight or branched chain. Halo means fluoro, chloro, bromo or iodo. Alpha-branched means that the carbon atom attached to the 25-ring position is a secondary carbon 2 atom linked to two further carbon atoms. When R is alkyl of 5 or more carbon atoms, the remainder of the alkyl chain may be straight or branched chain.
Preferred compounds of the formula I are those wherein R is
4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy. Also preferred 2 are compounds of the formula I wherein R is a Cj or Cg cycloalkyl or cycloalkenyl group which may optionally be substituted by one or more C^-C^ alkyl groups, cyclopentyl being particularly preferred. In another group of preferred compounds R^ is 2 cyclobutyl. In a further group of preferred compounds R is a 5 or 6 membered oxygen or sulphur containing heterocyclic ring, particularly a 3-thienyl or 3-furyl ring, which may optionally be substituted by one or more C.-C. alkyl groups or halogen atoms.
- * 2
In a yet further group of preferred compounds, R is a C^-Cg alkylthioalkyl group, particularly a 1-raethylthioethyl group.
In accordance with the invention the compounds of formula I wherein R? is OH and the double bond is absent or wherein the 1 4 double bond is present and R is absent and R is 4’-(alpha-Loleandrosyl)-alpha-L-oleandrosyloxy are prepared by fermenting an avermectin producing organism, such as a strain of the organism Streptomyces avermitills ATCC 31267, 31271 or 31272, in the presence of the appropriate carboxylic acid of the formula R CO.H, 2 wherein R is as previously defined, or a salt, ester, or amide thereof or oxidative precursor therefor. The acid is added to the fermentation either at the time of inoculation or at intervals during the fermentation. Production of the compounds of formula (I) may be monitored by removing samples from the fermentation, extracting with an organic solvent and following the appearance of the compound of formula (I) by chromatography, for example using high pressure liquid chromatography. Incubation is continued until the yield of the compound of formula (I) has been maximised, generally for a period of from 4 to 6 days.
A preferred level of each addition of the carboxylic acid or derivative thereof is between 0.05 and 1.0 grams per litre. The best yields of the compounds of formula (I) are obtained by gradually adding the acid to the fermentation., for example by daily additions of the acid or derivative thereof over a period of several days. The acid is preferably added as a salt, such as the sodium or ammonium salt, but may be added as an ester, such as the methyl or ethyl ester or as an amide. Alternative substrates which may be used in the fermentation are derivatives which are oxidative precursors for the carboxylic acids; thus, for example suitable substrates would be aminoacids of the formula
2 R CHCNHpcOzH, glyoxylic acids of the formula R COCO^H, methylamine derivatives of the formula R^CH.NH?, substituted lower 2 2 2 alkanoic acids of the formula R (CB-) CO_H wherein n is 2, 4 or 6, 2^ 2 methanol derivatives of the formula R CH?0H or aldehydes of the 2 2 formula R CHO, wherein R is as previously defined. The media used for the fermentation may be a conventional complex media containing assimilable sources of carbon, nitrogen and other trace elements. However we have found that for better results a strain of the organism derived from Streptomyces avermitilis ATCC 31271 which gives improved yields of a compound of formula I when
AP 0 0 0 0 3 7
PLC 414/417 cultured in a semi-defined medium may be used and this has the advantage that crude solvent extracts contain significantly less unwanted material which greatly simplifies the subsequent isolation and purification stages. Such a strain has been deposited with the National Collection of Industrial Bacteria (NCIB) on 19th July, 1985 under the accession number NCIB 12121. The morphological and cultural characteristics of this strain are otherwise generally as described in British Patent specification no. 1573955 for strain ATCC 31267.
After fermentation for a period of several days at a temperature preferably in the range of from 24 to 33°C,the fermentation broth is centrifuged or filtered and the mycelial cake is extracted with acetone or methanol. The solvent extract is concentrated and the desired product is then extracted into a water-immiscible organic solvent, such as methylene chloride, ethyl acetate, chloroform, butanol or methyl isobutyl ketone. The solvent extract is concentrated and the crude product containing the compounds of formula (I) is further purified as necessary by chromatography, for example using preparative reverse phase, high pressure liquid chromatography.
The product is generally obtained as a mixture of the compounds of formula (I) wherein R is 4’-(alpha-L-oleandrosyl)alpha-L-oleandrosyloxy, R^ is OH and the double bond absent or 3 is absent and the double bond is present and wherein R is H or
CH^; however the proportions can vary depending on the particular carboxylic acid employed and the conditions used.
We have found that a broad range of carboxylic acids as 2 defined by R CC^H may be added to the fermentation to yield avermectins having a novel substituent group at the 25-position. Examples of particular acids which may be employed include the following:
2-methylvaleric acid
2-methylpent-4-enoic acid
2-methylthiopropionic acid
2-cyclopropyl propionic acid cyclobutane carboxylic acid
PLC 414/417 cyclopentane carboxylic acid cyclohexane carboxylic acid cycloheptane carboxylic acid
2- methylcyclopropane carboxylic acid
3- cyclohexene-l-carboxylic acid and thiophene-3-carboxylic acid
In one particular and preferred aspect of the invention, the fermentation is performed in the presence of cyclopentane carboxylic acid sodium salt to yield predominantly the compound of
2 formula (I) wherein R is OH, the double bond is absent, R is
4 cyclopentyl, R is CH^ and R is 4'-(alpha-L-oleandrosyl)-alpha4-oleandrosyloxy.
In another preferred aspect of the invention, the fermentation is performed in the presence of thiophene-3carboxylic acid sodium salt to yield predominantly the compound of
2 formula (I) wherein R is OH, the double bond is absent, R is
4 thien-3-yl, R is CH^ and R is 4’-(alpha-L-oleandrosyl)-alpha4-oleandrosyloxy.
In a further preferred aspect of the invention the fermentation is performed in the presence of 2-methylthiopropionic acid sodium salt to yield predominantly the compound of formula
2 (I) wherein R is OH, the double bond is absent, R is
4
1-methylthioethyl, is CH and R is 4'-(alpha-L-oleandrosyl)alpha-4-oleandrosyloxy.
Compounds of the formula (I) wherein the double bond is present and R^ Is absent may alternatively be prepared from the corresponding compound of formula (I) wherein is OH and the double bond is absent by a dehydration reaction. The reaction is performed by first selectively protecting the hydroxyl groups at the 5 and 4 positions, e.g. as the t-butyldimethylsilyloxy acetyl derivative, then reacting with a substituted thiocarbonyl halide, such as (4-methylphenoxy)thiocarbonyl chloride, followed by heating in a high boiling point solvent, e.g. trichlorobenzene, to effect the dehydration. The product is finally deprotected to give the unsaturated compound. These steps together with appropriate reagents and reaction conditions are described in United States patent 4328335.
AP 0 0 0 0 3 7 dt r /,1 /, //. 11
The compounds of formula I wherein R is H may also be 3 prepared from the corresponding compounds wherein R is CH^ by demethylation. This reaction is achieved by treating the
5-methoxy compound, or a suitably protected derivative thereof, with mercuric acetate and hydrolysing the resulting 3-acetoxy enol ether with dilute acid to give the 5-keto compound. This is then reduced using, for example, sodium borohydride to yield the
5-hydroxy derivative. Appropriate reagents and reaction conditions for these steps are described in United States patent 4423209.
The compounds of formula I wherein R^ is H and the double bond is absent can be prepared from the corresponding compound wherein the double bond is present and R^ is absent, by selective catalytic hydrogenation using an appropriate catalyst. For example the reduction may be achieved using tris(triphenylphosphine) rhodium (I) chloride as described in European patent application publication no. 0001689.
The compounds of formula (I) wherein R is H are prepared 4 from the corresponding compounds wherein R is
4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy by removing the 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrose group by mild hydrolysis with an acid in an aqueous organic solvent to yield the aglycone having a hydroxy group at the 13-position; this is then halogenated, for example by reaction with a benzene sulphonyl halide, to yield the 13-deoxy-13-halo derivative which is finally selectively reduced, for example using tributyltin hydride. In order to avoid unwanted side reactions it is desirable to protect any other hydroxy groups which may be present, for example using a tert-butyldimethylsilyl group. This is then readily removed after the halogenation or reduction step by treatment with methanol containing a trace of acid. All these steps together with appropriate reagents and reaction conditions for their performance are described in European patent application publication no. 0002615.
1
Compounds of the formula (I) wherein R is H, R is either H or OH and the double bond is absent, may also be prepared by adding the appropriate carboxylic acid, or a salt, ester or amide
PT C 41Δ/Λ17 thereof or oxidative precursor therefor, to a fermentation of a milbemycin producing organism, and isolating the desired milbemycin derivative having an unnatural substituent group at the 25-position. Examples of milbemycin producing organisms include for instance Streptomyces hygroscopicus strain NRRL 5739 as described in British Patent Sepcification no. 1390336,
Streptomyces cyaneogrlseus subsp. noncyanogenus NRRL 15773 as described in European patent application publication no. 0170006 and Streptomyces thermoarchaenis NCIB 12015 as described in GB 2166436A.
The compounds of the invention are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasiticides, insecticides and acaricides.
Thus the compounds are effective in treating a variety of conditions caused by endoparasites including, in particular, helminthiasis which is most frequently caused by a group of parasitic worms described as nematodes and which can cause severe economic losses In swine, sheep, horses and cattle as well as affecting domestic animals and poultry. The compounds are also effective against other nematodes which affect various species of animals including, for example, Dirofilaria in dogs and various parasites which can infect humans including gastro-intestinal parasites such as Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, Enterobius and parasites which are found in the blood or other tissues and organs such as filiarial worms and the extra intestinal stages of Strongyloides and Trichinella.
The compounds are also of value in treating ectoparasite infections including in particular arthropod ectoparasites of animals and birds such as ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae which can affect cattle and horses.
The compounds are also insecticides active against household pests such as the cockroach, clothes moth, carpet beetle and the housefly as well as being useful against insect pests of stored grain and of agricultural plants such as spider mites, aphids, caterpillars and against migratory orthopterans such as locusts.
AP 0 0 0 0 3 7
PLC 414/617
The compounds of formula (I) are administered as a formulation appropriate to the specific use envisaged and to the particular species of host animal being treated and the parasite or insect involved. For use as an anthelmintic the compounds may be administered orally in the form of a capsule, bolus, tablet or preferably a liquid drench, or alternatively, they may be administered by injection or as an implant. Such formulations are prepared in a conventional manner in accordance with standard veterinary practice. Thus capsules, boluses or tablets may be prepared by mixing the active ingredient with a suitable finely divided diluent or carrier additionally containing a disintigrating agent and/or binder such as starch, lactose, talc, magnesium stearate etc. A drench formulation may be prepared by dispersing the active ingredient in an aqueous solution together with dispersing or wetting agents etc. and injectable formulations may be prepared in the form of a sterile solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. These formulations will vary with regard to the weight of active compound depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host. Generally for oral administration a dose of from about 0.001 to 10 mg per Kg of animal body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but of course there can be instances where higher or lower dosage ranges are indicated and such are within the scope of this invention.
As an alternative the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.
For use as an insecticide and for treating agricultural pests the compounds are applied as sprays, dusts, emulsions and the like in ac0>rdance with standard agricultural practice.
The invention is illustrated by the following Examples in which Examples 1 to 19 are Examples of the preparation of compounds of the formula (I), Example 20 is an example of a drench formulation and Examples 21 and 22 illustrate the antiparasitic and insecticidal activity of the compounds.
DT r /.1 /. //. Π
EXAMPLE 1
25-Cyclopentyl-avermectin A2
A suspension of a slope culture of S. avermitilis NCIB 12121 was inoculated into 600 mis of a medium containing lactose (12.Og), distillers solubles (8.0g) and yeast extract (3.0g), contained in a 3 litre flask, and incubated at 28°C for 3 days.
The inoculum was used to inoculate 16 litres of a medium containing soluble starch (640g), ammonium sulphate (32g) , dipotassium hydrogen phosphate (16g), sodium chloride (16g), magnesium sulphate 7^0 (16g), calcium carbonate (32g), soluble yeast extract (6.4g), ferrous sulphate 7^0 (0.016g), zinc sulphate 7^0 (0.016g) and manganese chloride 4^0 (0.016g), contained in a 20 litre fermenter. The fermentation was incubated at 28°C, with agitation at 250 r.p.m. and aerated at 15 litres per minute. Cyclopentane carboxylic acid sodium salt (1.6g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium was removed by filtration and extracted with acetone: ΙΝ-hydrochloric acid (100:1; 3x7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2x5 litres). The methylene chloride extract was concentrated to dryness to give the crude product as a mobile oil which was dissolved in diethyl ether and added to a column of silica gel (1 kg). The column was eluted with diethyl ether collecting 100 ml fractions. Fractions 20-40 were combined and the solvent evaporated to yield partially purified material. The product was dissolved in a mixture of methanol and water (4:1) and chromatographed on a C18 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using the same solvent at a flow rate of 100 ml per minute. Fractions 35 to 50 containing the desired product were combined and rechromatographed on a CIS Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (4:1) at a flow rate of 9 mis. per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein is OH,
AP 0 0 0 0 3 7 pre 414/Λ17
II
3 A the double bond is absent, R is cyclopentyl, RJ is CH^ and R is 4’-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy as a white powder, m.p. 150.5-151eC. The structure of the product was confirmed by mass spectrometry and by C13 nuclear magnetic resonance spectroscopy as follows:
Fast atom bombardment mass spectrometry was performed on a VG Model 7O7OE mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)+ observed at m/e 939 (theoretical 939).
Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 335, 317, 275, 257, 251, 233, 205, 181, 179, 145, 127, 113, 111, 95 and 87.
The 13C nuclear magnetic resonance spectral data were obtained on a Brucker Model WM-250 spectrometer with a sample concentration of 20 mg/ml in deuterochloroform. The chemical shifts in parts per million relative to tetramethylsilane were: 14.1, 15.3, 17.8, 18.5, 19.9, 20.3, 24.6, 25.9, 26.2, 29.3, 34.4 (2C), 34.7, 36.7, 37.8, 39.8, 40.5, 41.0, 41.3, 45.8, 56.4, 56.6,
57.8, 67.4; 67.6, 68.0, 68.3, 68.7, 69.9, 70.5, 76.0, 77.6 (2C),
78.3, 79.5, 80.7 (2C), 81.8, 94.9, 98.7, 99.8, 117.7, 118.5,
119.8, 125.0, 135.8, 136.3, 137.8, 140.1 and 173.8.
EXAMPLE 2
A suspension of a slope culture of S. avermitilis ATCC 31271 was inoculated into 50 mis of a medium containing lactose (l.Og), distillers solubles (0.75g) and yeast extract (0.25g), contained In a 350 ml flask, and incubated at 28°C for 3 days. This inoculum (4 mis) was used to inoculate each of 50 flasks containing 50 mis of medium containing corn starch (2.0g), soya flour (0.35g) and yeast extract (0.25g) contained in a 350 ml flask, and the flasks were incubated at 28°C.
After 24 hours, cyclopentane carboxylic acid sodium salt (5 mg) was added to each flask and incubation was continued for a further 5 days.. After this time the contents of the flasks were bulked and the mycelium separated by centrifugation. The mycelium was extracted with acetone:ΙΝ-hydrochloric acid (100:1) and the
PLC 414/417 acetone extract concentrated to dryness. The extract was analysed by high pressure liquid chromatography and was shown to contain a product identical with the product of Example 1.
EXAMPLE 3
An inoculum was prepared as described in Example 1 and used to inoculate 50 mis of the medium as used in Example 1, contained in 350 ml flasks. After incubation for 24 hours, 2-aminocyclopentyl acetic acid (cyclopentylglycine) (5 mg) was added and the fermentation was continued for a further 5 days. The product was recovered by extraction of the mycelium with acetone and methylene chloride. The extract was analysed by HPLC which indicated that the product contained a compound identical to the product of Example 1.
EXAMPLE 4
The conditions of Example 3 were followed except that cyclopentyl methanol was used as substrate with similar results.
EXAMPLE 5
The conditions of Example 3 were followed except that the methyl ester of cyclopentane carboxylic acid, dissolved in methanol, was used as substrate with similar results.
EXAMPLE 6
The conditions of Example 3 were followed except that cyclopentane carboxylic acid, dissolved in methanol was used as substrate with similar results.
EXAMPLE 7
25-(Thien-3-yl)avermectin
A suspension of a slope culture of S. avermitilis NCIB 12121 was inoculated into 600-mis of a medium containing lactose (12.Og), distillers solubles (8.0g) and yeast extract (3.0g), contained in a 3 litre flask, and incubated at 28°C for 3 days.
The inoculum was used to inoculate 16 litres of a medium containing soluble starch (640g), ammonium sulphate (32g), £ £ 0 0 0 0 dV
PLC 414/417 dipotassium hydrogen phosphate (16g), sodium chloride (16g), magnesium sulphate 7H2O (16g), calcium carbonate (32g), soluble yeast extract (6.4g), ferrous sulphate 7H2O (0.016g), zinc sulphate 7H2O (0.016g) and manganese chloride 4H20 (0.016g), contained in a 20 litre fermenter. The fermentation was incubated at 28°C, with agitation at 250 r.p.m. and aerated at 15 litres per minute. Thiophene-3-carboxylic acid sodium salt (1.6g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours. After this time the mycelium was removed by filtration and extracted with acetone: lN-hydrochloric acid (100:1; 3x7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2x5 litres). The methylene chloride extract was concentrated to dryness to give the crude product as a mobile oil which was dissolved in diethyl ether and added to a column of silica gel (1 kg). The column was eluted with diethyl ether collecting 200 ml fractions. Fractions 32-45 were combined and the solvent evaporated to yield partially purified material. The product was dissolved in a mixture of methanol and water (3:1) and chromatographed on a C18
Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using the same solvent at a flow rate of 100 ml per minute. Fractions 27 to 36 containing the desired product were combined and rechromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (3:1) at a flow rate of 9 mis. per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R1 is OH,
3 4 the double bond is absent, R is thien-3-yl, R is CH^ and R is 4’-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy as a white powder, m.p. 167°C. The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG Model 7O7OE mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na) observed at m/e 953 (theoretical 953).
dt r /,1/,//,17
Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were; 349, 331, 275, 265, 257, 247, 237, 219, 195, 145, 127, 113, 95 and 87.
EXAMPLE 8
A vegetative cell suspension of S. avermitilis NCIB 12121, held at -60eC in 10X v/v aqueous (2 mis) glycerol was inoculated into 50 ml of medium containing lactose (1.0 g), distillers solubles (0.75 g) amd yeast extract (0.25 g) contained in a 300 ml conical flask and incubated at 28°C for 24 hours, with shaking.
The inoculum was then added to 600 ml of the above medium contained in a 3 litre flask and the mixture was incubated at 28°C for 24 hours with shaking. The product was used to inoculate 10 litres of the above medium contained in a 16 litre fermenter which was incubated at 28°C for 24 hours at an agitation speed of 350 r.p.m. with aeration at 10 litres of air per minute. This fermentation (600 ml) was used to inoculate 16 litres of a medium containing partially hydrolysed starch (640 g) ammonium sulphate (32 g), dipotassium hydrogen phosphate (16g), sodium chloride (16 g) magnesium sulphate 7Ή2Ο (16 g), calcium carbonate (32 g), soluble yeast extract (6.4 g), ferrous sulphate 711^0 (0.016g), zinc sulphate 71^0 (0.016 g), and manganese chloride 41^0 (0.016 g), contained in a 20 litre fermenter. The fermentation was incubated at 28eC, fcith agitation at 350 r.p.m. and aerated at 15 litres per minute. Cyclobutane carboxylic acid sodium salt (1.6 g) was added after 24 hours and again after 48 and 72 hours incubation and the fermentation was continued for 120 hours.
After this time the mycelium was removed by filtration and extracted with acetone (3x7 litres). The extract was concentrated to approximately 2 litres under reduced pressure and extracted with methylene chloride (2x5 litres). The methylene chloride was concentrated to dryness to give the crude product as a mobile oil. This was taken up in iso-octane (150 ml) and the solution extracted with a mixture of methanol (95 ml) and water (5 ml). Evaporation of the methanolic extract gave partially purified material which was separated into its individual components by high pressure liquid chromatography as follows:
The residue was dissolved in a little methanol and
L £ 0 0 0 0 dV
PLC 414/417 chromatographed in a C18 Micro-Bondapack column (50 mm x 50 cm) in a Waters Prep 500 high pressure liquid chromatograph using a mixture of methanol/water (4:1) at a flow rate of 100 ml per minute. Fractions 1 to 4 were combined and used in Example 9, fractions 5 to 9 were combined and used in Example 10, fractions 10 to 19 were combined and used in Example 11 and fractions 20 to 35 were combined and used in Example 12.
The combined fractions 1 to 4 from Example 8 were evaporated to dryness and the residue was re-chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (3:1) at a flow rate of 9mls per minute. The relevant fractions were combined, the solvent evaporated and the product subjected to a final purification on a Silica Spherisorb 5 micron (Trademark, HPLC Technology) column (10.5 mm x 25 cm) eluting with a mixture of methylene chloride and methanol (98:2) at a flow rate of 4 mis per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R1 is OH, the double bond Is
3 4 absent, R is cyclobutyl, R is H and R is 4'-(alphaL-oleandrosyl)-L-oleandrosyloxy, as a white powder, m.p.
110-112°C. The structure of the product was confirmed by mass spectrometry as follows:Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene •ψ· glycol with solid sodium chloride. (M + Na) observed at m/e 911 (theoretical 911).
Electron impact mass spectrometry was performed using a VG Model 7O7OF mass spectrometer. The m/e values for the principal fragments were: 321, 303, 261, 145, 127, 113,
257, 237, 219, 209, 191, 179, 167 111, 95 and 87.
EXAMPLE 10 1 3
25-Cyclobutyl-avermectin A2 (R =* OH, R = CH^)
The combined fractions 5 to 9 from Example 8 were evaporated to dryness and the residue was rechromatographed twice on a C18 Zorbax ODS (Trademark, Dupont) column, (21 mm x 25 cm) eluting
PLC 414/417 with a methanol and water mixture (77:23) at a flow rate of 9 mis per minute. Suitable fractions were combined and evaporated to yield the compound of formula (I) wherein R. is OH, the double
3 1 4 bond is absent, R is cyclobutyl, R is CH^ and R is 4'-(alpha-L-oleandrosyl)-L-oleandrosyloxy as a white powder m.p. 135-140eC.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)+ observed at m/e 925 (theoretical 925).
Electron impact mass spectrometry was performed using a VG Model 7O7OF mass spectrometer. The m/e values for the principal fragments were: 596, 454, 321, 303, 275, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.
EXAMPLE 11
25-Cyclobutyl-avermectin BI (22,23-Double bond present, R = H)
The combined fractions 10 to 19 from Example 8 were evaporated to dryness and the residue dissolved in methanol and chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of methanol and water (4:1) at a flow rate of 9 mis per minute. The relevant fractions were combined and the solvent evaporated to give a product which was re-chromatographed on a Silica Zorbax SIL (Trademark, Dupont) column (21 mm x 25 cm) eluting with a mixture of dichloromethane and methanol (98.5:1.5) at a flow rate of 9 mis per minute. The relevant fractions were combined and the solvent evaporated to yield the compound of formula (I) wherein R* Is absent, the double
3 4 bond is present, R is cyclobutyl, R is H and R is 4’-(alpha-L-oleandrosyl)-L- oleandrosyloxy, as a white powder m.p. 135-138eC. The structure of the product was confirmed by mass spectrometry as follows:Fast atom bombardment mass spectrometry was performed on a VG Model 7O7OE mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)+ observed ad m/e 893 (theoretical 893).
AP 0 0 0 0 3 7
PLC 414/417
Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 303, 261, 257, 219, 191, 167, 145, 127, 113,
111, 95 and 87.
EXAMPLE 12
25-Cyclobutyl-avermectin Al (22,23-Double bond present, R » CH^)
The combined fractions 20 to 35 from Example 8 were evaporated to dryness and the residue chromatographed on a C18 Zorbax ODS (Trademark, Dupont) column (21 mm x 25 cm) at a flow rate of 9 mis per minute. The relevant fractions were combined, the solvent evaporated and the product was rechromatographed on a Silica Sperisorb 5 micron (Trademark, HPLC Technology) column (10.5 mm x 25 cm) eluting with a mixture of dichloromethane and methanol (98.5 : 1.5) at a flow rate of 4 mis per minute. Combination of the relevant fractions followed by evaporation gave the compound of formula (I) wherein R^ is absent, the double bond
3 4 is present, R is cyclobutyl, R is CH^ and R is 4’-(alpha-L-oleandrosyl)-L- oleandrosyloxy as a white powder m.p. 120-124eC. The structure of the product was confirmed by mass spectrometry as follows:Fast atom bombardment mass spectrometry was performed on a VG Model 7O7OE mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)+ observed at m/e 907 (theoretical 907).
Electron impact mass spectrometry was performed using a VG Model 7O7OF mass spectrometer. The m/e values for the principal fragments were: 578, 303, 275, 257, 219, 191, 167, 145, 127, 113,
111, 95 and 87.
EXAMPLE 13
25-(Cyclohex-3-enyl)avermectin A2
The medium and conditions of Example 1 were followed except that 3-cyclohexenoic acid sodium salt was used as the substrate to yield the compound of formula I wherein R1 is OH, the double bond
3 4 is absent, R is cyclohex-3-enyl, R is CH^ and R is 4'-(alpha-L-oleandrosyl)-alpha-L- oleandrosyloxy as a white powder mpt. 131-5eC.
dt r / 1 / / / i
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na ) observed at m/e 951 (theoretical 951).
Electron impact mass spectrometry was performed using a VG Model 707CF mass spectrometer. The m/e values for the principal fragments were: 624,480, 347, 329, 275, 263,
245, 235, 217, 205, 193, 179, 145, 127, 113, 111, 35 and 87.
EXAMPLE 14
25-Cyclohexyl avermectin A2
The medium and conditions of Example 1 were followed except that cyclohexane carboxylic acid sodium salt was used as the substrate to yield the compound of formula I wherein R1 is OH, R2 is cyclohexyl, R9 is CH3 and R4 is 4'(alpha-oleandroxyl)-alpha-L-oleandrosyloxy as a white powder mpt. 112-117°C.
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG Model 7070E mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M +Na)+ observed at m/e 953 (theoretical 953).
Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 624, 482, 349, 331, 275, 265,
247, 237, 219, 207, 195, 179, 145, 127, 113, 111, 95 and 87.
AP 0 0 0 0 3 7
EXAMPLE 15
25-(1-Methylthioethyl)avermectin A2
The medium and conditions of Example 1 were followed except that 2-methylthiopropionic acid sodium salt was used as the substrate to yield the compound of formula I wherein R-] is OH, R2 is 1-methylthioethyl, R9 is CH3 and R4 is 4'-(alpha-L-oleandroxyl)-oleandroxyloxy as a white powder, m.p. 134-138OC.
BAD OFUQ,nAL
The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG Model 7O7OE mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)+ observed at m/e 945 (theoretical 945).
Electron impact mass spectrometry was performed using a VG Model 7070F mass spectrometer. The m/e values for the principal fragments were: 341, 323, 275, 263, 257, 239, 211, 187, 179, 145, 127, 113, 111, 95 and 87.
EXAMPLE 16
25-(2-Methylcyclopropyl)avermectin A2
The medium and conditions of Example 1 were followed except that 2-methylcyclopropane carboxylic acid sodium salt was used as the substrate to yield the compound of formula I wherein is OH, 2 3
R is 2-methylcyclopropyl, R is CH^ and R^ is 4’-(alpha-Loleandrosyl)-oleandroxyloxy, as a white powder, m.p. 147-150°C.
' The structure of the product was confirmed by mass spectrometry as follows:
Fast atom bombardment mass spectrometry was performed on a VG Model 7O7OE mass spectrometer using a sample matrix of triethylene glycol with solid sodium chloride. (M + Na)+ observed at m/e 925 (theoretical 925).
Electron impact mass spectrometry was performed using a VG Model 7O7OF mass spectrometer. The m/e values for the principal fragments were: 596, 454, 303, 275, 237, 219, 209, 191, 179, 167, 145, 127, 113, 111, 95 and 87.
EXAMPLE 17
The procedure of Example 1 was followed but using the sodium salt of the following carboxylic acids as substrate instead of cyclopentane carboxylic acid to yield the appropriate 25-substituted avermectins of formula (I) wherein R is OH and the dt r /,1/.//120 double bond is absent or wherein the double bond is present and 3 4 is absent, R is H or OH and R is 4'-(alpha-L-oleandrosyl)-alphaL-oleandrosyloxy:
2-methylvaleric acid
2.3- dimethylbutyric acid 2-methylhexanoic acid 2-methylpent-4-enoic acid 2-methylpentanoic acid
2- cyclopropyl propionic acid cycloheptane carboxylic acid
4.4- difluorocyclohexane carboxylic acid 4-methylenecyclohexane carboxylic acid
3- methylcyclohexane carboxylic acid cyclopentene-l-carboxylic acid 1-cyclohexene carboxylic acid tetrahydropyran-4-carboxylic acid thiophene-2-carboxylic acid 3-furoic acid and 2-chloro-thiophene-4-carboxylic acid.
EXAMPLE 18
25-Cyclobutyl-22,23-dihydro-avermectin BI
The product of Example 11 in benzene is hydrogenated in the presence of tris(triphenylphosphine)rhodium (I) chloride according to the procedure of EP-A-OOO1689 to yield the corresponding compound of formula (I) wherein R^ is H and the double bond is absent.
EXAMPLE 19
13-Deoxy-25-cyclopentyl-avermectin A2-aglycone
The product of Example 1 is treated with dilute sulphuric acid at room temperature and the resulting aglycone product is isolated and reacted with t-butyldimethylsilylchloride in dimethylformamide to provide the 23-O-t-butyldimethylsilyl aglycone derivative. This is dissolved in methylene chloride containing 4-dimethylaminopyridine and diisopropylethylamine, cooled in ice and treated dropwise with 4-nitrobenzeneAP 0 0 0 0 3 7 dt r ζ,ι L· //, ? 7 sulphonylchloride to yield the 13-chloro-13-deoxy product. This is finally dehalogenated by reaction with tributyltinhydride and deprotected with methanol containing a trace of para-toluene sulphonic acid following the procedures described in EP-A-0002615 1 4 to provide the compound of the formula I wherein R and R are
2 each H, R is OH, the double bond is absent and R is cyclopentyl.
EXAMPLE 20
Drench Formulation
The product of any one of the preceding Examples was dissolved in polyethylene glycol (average molecular weight 300) to give a solution containing 400 micrograms/ml for use as a drench formulation.
EXAMPLE 21
Anthelmintic Activity
Anthelmintic activity was evaluated against Caenorhabditis elegans using the in vitro screening test described by K. G. Simpkin and G. L. Coles in Parisitology, 1979, 79, 19. The products of Examples 1, 7 and 9-16 all killed 100Z of the worms at a well concentration of 0.1 micrograms per ml.
EXAMPLE 22
Insecticidal Activity
Activity against adult house fly Musca domestica is demonstrated using a standard test procedure in which the flies are anaesthetised under carbon dioxide and 0.1 microlitres of acetone containing the test compound is deposited on the thorax of female flies. The product of Examples 1, 7 and 9-16 all killed 100% of the treated flies at a dose of 0.01 micrograms per fly.

Claims (4)

1. A compound having the formula:
wherein the broken line at the 22-23 position represents an optional double bond and wherein Rx is H or OH and the double bond is absent, or, the double bond is present and RX is absent;
R is an alpha-branched C^-Cg alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group; a C.-Co cycloalkylalkyl group 0 o wherein the alkyl group is an alpha-branched C^-C- alkyl group; a C^-Cg cycloalkyl or C^-Cg cycloalkenyl group, either of which may optionally be substituted by methylene or one or more C^-C^ alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more C.-C, alkyl groups or halo atoms;
3 1 4
R is hydrogen or methyl;
R is H or a 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group of the formula:
AP 0 0 0 0 3 7
CH.
CH.
CH
3-CT CH^O with the proviso that when r2 is alkyl it is not isopropyl or sec-butyl; and is H, R^ is OH, and the double bond is absent, R2 is not 2-buten-2-yl 2-penten-2-yl or 4-methyl2-penten-2-yl.
2. A compound of the formula I as claimed in claim 1 wherein R^ is 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy.
3. A compound as claimed in claim 2 wherein r2 is a C5 or C5 cycloalkyl or cycloalkenyl group which may optionally be substituted by one or more C1-C4 alkyl groups.
4. A compound as claimed in claim 3 wherein R2 is cyclopentyl 5. A or cyclohexyl, compound as claimed in claim 2 wherein R2 is cyclobutyl. 6. A compound as claimed in claim 2 wherein R2 is
a 5 or 6 membered oxygen or sulphur containing heterocyclic ring which may optionally be substituted by one or more C1-C4 alkyl groups or halogen atoms.
7. A compound as claimed in claim 6 wherein R2 is 3-thienyl. 8. A compound as claimed in claim 2 wherein R2 is C3- Cg alkylthioalkyl group. 9. A compound as claimed in claim 8 wherein R2 is
1-methylthioethyl.
10. A process for producing a novel avermectin derivative having an unnatural substituent group at the 25-position which comprises adding a carboxylic acid, or a salt, ester or amide thereof or oxidative precursor therefor, to a fermentation of an avermectin producing organism, and isolating the novel avermectin derivative.
11. A process for producing a compound of the formula (I) as claimed in claim 1 which comprises fermenting an avermectin producing strain of the organism Streptomyces avermitilis in the presence of a carboxylic acid of the formula R^CC^H wherein r2 is defined as in claim 1, or a salt, ester or amide thereof or oxidative precursor therefor, and isolating the compound of formula (I) wherein R1 is
OH and the double bond is absent or
PTC did/417
1 4 wherein the double bond is present and R is absent and R is 4’-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy and, if desired, reducing the compound wherein the double bond is present and is absent to obtain the compound of formula (I) wherein R3, is H and the double bond is absent or, if desired, removing the
4-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy group by hydrolysis followed by halogenation and reduction to yield the compound of 4 formula (I) wherein R is H.
12. A process as claimed in claim 11 wherein the organism is Streptomyces avermitilis NCIB 12121.
13. A composition for the treatment and prevention of parasitic infections in humans and animals, including ectoparasiticidal, insecticidal, acaricidal and anthelmintic compositions, which comprises a compound of the formula (I) as claimed in any one of claims 1 to 9 together with an inert diluent or carrier.
14. A composition as claimed in claim 13 in the form of a liquid drench or an oral or injectable formulation.
- 15. A composition as claimed in claim 13 in the form of an animal feedstuff or in the form of a premix or supplement for addition to animal feed.
16. A compound of the formula I as claimed in any one of claims 1 to 9 or a composition thereof as claimed in claims 13 to 15 for use in the treatment or prevention of parasitic infections in humans and animals.
17. A method of combating insect or parasite infections or infestations, including parasitic conditions in humans and animals and agricultural or horticultural pest infestations, which comprises applying an effective amount of a compound of the formula (I) as claimed in any one of claims 1 to 9 to the organism responsible for said infection or infestation or to the location thereof.
AP 0 o 0 0 3 7
PLC 414/417
- 25 18. A compound of the general formula I set out in claim
1 substantially as herein described with reference to the accompanying examples.
19. A process for producing a novel avermectin derivative having the general formula I substantially as herein described with reference to the accompanying examples.
20. A composition for the treatment and prevention of parasitic infections in humans and animals including a compound of the general formula I, substantially as herein described with reference to the accompanying examples.
21. The use of a compound of general formula I in the manufacture of a formulation for use in the treatment of parasitic conditions in humans or animals or to combat agricultural or horticultural pest infestations.
•i- /
The invention provides novel compounds having the formula:
ABSTRACT wherein the broken line at the 22-23 position represents an optional double bond and wherein R^ is H or OH and the double bond is absent, or, the double bond is present and is absent;
2 R is an alpha-branched Cg-Cg alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylchioalkyl group; a Cg-Cg cycloalkyl, C^-Cg cycloalkenyl or
Cj-Cg cycloalkylalkyl group, any of which may optionally be substituted by methylene or one or more C^-C^ alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may optionally be substituted by one or 3 more C..-C, alkyl groups or halo atoms; R is hydrogen or methyl;
4 ·*· 4
R is H or 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy, with the proviso that when R is alkyl it is not isopropyl or 4 1 sec-butyl; when R is H, R is H, and the double bond is absent,
2 4 1
R is not methyl or ethyl; and when R is H, R is OH, and the double bond is absent, R is not 2-buten-2-yl, 2-pentene-2-yl or 4-methyl-2—pentene-2-yl.
The compounds are broad spectrum antiparasitic agents having utility as anthelmintics» ectoparasiticides, insecticides and acaricides. The invention also provides a process for producing the novel avermectin and milbemycin derivatives by adding a carboxylic acid or derivative thereof to a fermentation of an avermectin or milbemycin producing organism.
APAP/P/1986/000040A 1985-07-27 1986-08-01 Antiparasitic agents and process of their preparation. AP37A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB858518999A GB8518999D0 (en) 1985-07-27 1985-07-27 Antiparasitic agents
GB858520069A GB8520069D0 (en) 1985-08-09 1985-08-09 Anti-parasitic agents
GB868610063A GB8610063D0 (en) 1986-04-24 1986-04-24 Antiparasitic agents
GB868610862A GB8610862D0 (en) 1986-05-02 1986-05-02 Antiparasitic agents

Publications (2)

Publication Number Publication Date
AP8600040A0 AP8600040A0 (en) 1986-08-01
AP37A true AP37A (en) 1989-03-11

Family

ID=27449680

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1986/000040A AP37A (en) 1985-07-27 1986-08-01 Antiparasitic agents and process of their preparation.

Country Status (31)

Country Link
US (2) US5089480A (en)
EP (1) EP0214731B1 (en)
JP (1) JPH0637501B2 (en)
CN (1) CN1007266B (en)
AP (1) AP37A (en)
AU (1) AU572402B2 (en)
BG (1) BG46601A3 (en)
CA (1) CA1339480C (en)
CY (1) CY1719A (en)
DE (1) DE3676396D1 (en)
DK (1) DK169036B1 (en)
ES (1) ES8800986A1 (en)
FI (1) FI87367C (en)
GR (1) GR861965B (en)
HK (1) HK65793A (en)
HU (1) HU195856B (en)
IE (1) IE58640B1 (en)
IL (1) IL79523A (en)
LU (1) LU88788I2 (en)
MA (1) MA20746A1 (en)
NL (1) NL950011I2 (en)
NO (2) NO165881C (en)
NZ (1) NZ216980A (en)
OA (1) OA08370A (en)
PH (1) PH23081A (en)
PL (1) PL153429B1 (en)
PT (1) PT83070B (en)
SK (1) SK278513B6 (en)
SU (1) SU1560059A3 (en)
UA (1) UA6345A1 (en)
YU (1) YU44294B (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR852232B (en) * 1984-09-14 1986-01-14 American Cyanamid Co
ES8802229A1 (en) * 1985-04-30 1988-04-16 Glaxo Group Ltd Macrolide antibiotics and their preparation
NZ217567A (en) * 1985-09-13 1988-07-28 Glaxo Group Ltd Avermectin/milbemycin derivatives
CA1287048C (en) * 1986-03-12 1991-07-30 Paul F. Lambeth Macrolide compounds
DE3750495T2 (en) * 1986-07-24 1995-02-23 Beecham Group Plc Milbemycin derivatives with parasiticidal activity, a process for their preparation and the compositions containing them.
EP0260537A1 (en) * 1986-09-12 1988-03-23 American Cyanamid Company 13-Deoxy-23-oxo(keto) and 23-imino derivatives of 13-deoxy C-076-aglycone compounds
US5019589A (en) * 1986-09-12 1991-05-28 American Cyanamid Company Δ23 -LL-F28249 compounds
ATE82017T1 (en) * 1986-09-12 1992-11-15 American Cyanamid Co 23-DEOXY DERIVATIVES OF LL-F28249 COMPOUNDS.
US4886828A (en) * 1986-09-12 1989-12-12 American Cyanamid Company Δ22 -derivatives of LL-F28249 compounds
US5149832A (en) * 1986-09-12 1992-09-22 American Cyanamid Company Mono and diacyl derivatives of ll-f28249 compounds
US5525506A (en) * 1987-01-23 1996-06-11 Pfizer Inc. Process for production of avermectins and cultures therefor
US5238848A (en) * 1987-01-23 1993-08-24 Pfizer Inc Cultures for production of avermectins
US5234831A (en) * 1987-01-23 1993-08-10 Pfizer Inc Cultures for production of B avermectins
EP0284176B1 (en) * 1987-01-23 1993-08-25 Pfizer Inc. Process for production of avermectins and cultures therefor
IN167980B (en) * 1987-01-23 1991-01-19 Pfizer
US4851428A (en) * 1987-03-06 1989-07-25 American Cyanamid Company Mono- and diepoxide derivatives of Δ22-LL-F28249 compounds
US4956479A (en) * 1987-03-06 1990-09-11 American Cyanamid Company 23-deoxy-27-chloro derivatives of LL-F28249 compounds
US4886830A (en) * 1987-03-06 1989-12-12 American Cyanamid Company Mono- and diepoxide derivatives of 23-deoxyl-LL-F28249 compounds
US4806527A (en) * 1987-03-16 1989-02-21 Merck & Co., Inc. Avermectin derivatives
NZ225364A (en) * 1987-07-20 1990-04-26 Merck & Co Inc 5,23-di-hydroxy 25-(4-methyl-hex-2-en-2-yl) milbemycin and parasiticidal compositions
JPS6431776A (en) * 1987-07-28 1989-02-02 Sankyo Co Novel macrolide compound and production thereof
GB8721647D0 (en) * 1987-09-15 1987-10-21 Pfizer Ltd Antiparasitic agents
US5240850A (en) * 1987-10-23 1993-08-31 Pfizer Inc. Cultures for production of avermectin aglycones
EP0313297B1 (en) * 1987-10-23 1993-05-19 Pfizer Inc. Process for production of avermectin aglycones and cultures therefor
EP0319142B1 (en) * 1987-11-03 1994-04-06 Beecham Group Plc Intermediates for the preparation of anthelmintic macrolide antibiotics
PT88952B (en) * 1987-11-09 1993-02-26 Pfizer PROCESS FOR THE PREPARATION OF ETHYLATED AVERMECTINS
GB8726730D0 (en) * 1987-11-14 1987-12-16 Pfizer Ltd Antiparasitic agents
GB8807280D0 (en) * 1988-03-26 1988-04-27 Pfizer Ltd Antiparasitic agents
GB8809232D0 (en) * 1988-04-19 1988-05-25 Pfizer Ltd Antiparasitic agents
GB8815967D0 (en) * 1988-07-05 1988-08-10 Pfizer Ltd Antiparasitic agents
US5015662A (en) * 1988-10-18 1991-05-14 Merck & Co., Inc. Anthelmintic bioconversion products
OA09249A (en) * 1988-12-19 1992-06-30 Lilly Co Eli Compounds of macrolides.
NZ231773A (en) * 1988-12-23 1992-09-25 Merck & Co Inc Avermectin derivatives, preparation and parasiticidal pharmaceutical compositions thereof
US5015630A (en) * 1989-01-19 1991-05-14 Merck & Co., Inc. 5-oxime avermectin derivatives
US4897383A (en) * 1989-02-13 1990-01-30 Merck & Co., Inc. Avermectin derivatives
US6001822A (en) * 1989-04-11 1999-12-14 Pfizer Inc. Antiparasitic formulations
US5057499A (en) * 1989-06-02 1991-10-15 Merck & Co. Inc. Avermectin derivatives
US5030622A (en) * 1989-06-02 1991-07-09 Merck & Co., Inc. Avermectin derivatives
US5023241A (en) * 1989-07-31 1991-06-11 Merck & Co., Inc. Avermectin derivatives
WO1991006552A1 (en) * 1989-10-30 1991-05-16 Eli Lilly And Company A83543 recovery process
US5830875A (en) * 1989-10-30 1998-11-03 Merck & Co., Inc. 24-and 25-substituted avermectin and milbemycin derivatives
US5188944A (en) * 1990-06-22 1993-02-23 Merck & Co., Inc. Process for the glycosylation of avermectin agylcones
US5208222A (en) * 1991-03-28 1993-05-04 Merck & Co., Inc. 4"-and 4'-alkylthio avermectin derivatives
US5240915A (en) * 1991-10-15 1993-08-31 Merck & Co., Inc. Avermectin derivatives
AU660205B2 (en) * 1991-12-23 1995-06-15 Virbac, Inc Systemic control of parasites
GB9201505D0 (en) * 1992-01-24 1992-03-11 Pfizer Ltd Antiparasitic agents
GB9205007D0 (en) * 1992-03-07 1992-04-22 Pfizer Ltd Antiparasitic agents
US6103504A (en) * 1992-03-25 2000-08-15 Pfizer Inc. Process for production of avermectins and cultures therefor
US5241083A (en) * 1992-07-01 1993-08-31 Merck & Co., Inc. Process for converting the 13-α-hydroxy group of avermectin aglycones
US5591606A (en) * 1992-11-06 1997-01-07 Dowelanco Process for the production of A83543 compounds with Saccharopolyspora spinosa
EP0670067B1 (en) * 1992-11-20 1997-05-07 Btg International Limited Image reconstruction
US5292647A (en) * 1992-11-30 1994-03-08 Eli Lilly And Company Strain of streptomyces for producing avermectins and processes therewith
US5411946A (en) * 1993-02-24 1995-05-02 Merck & Co., Inc. Avermectin derivatives
DK0688332T3 (en) * 1993-03-12 1997-10-13 Dowelanco New A83543 compounds and processes for their preparation.
GB9315108D0 (en) * 1993-07-21 1993-09-01 Pfizer Ltd Antiparasitic agents
ATE175240T1 (en) * 1993-07-23 1999-01-15 Pfizer PROCESS FOR THE PRECIPITATION OF NATURAL AVERMECTINS AND FERMENTATION PROCESS FOR THE PRODUCTION OF THE SAME
CZ287404B6 (en) * 1993-10-05 2000-11-15 Pfizer Process for preparing doramectin
TW327125B (en) * 1994-02-07 1998-02-21 Merck & Co Inc Composition and method for protecting against pine exhausted
DE4427766A1 (en) * 1994-08-05 1996-02-08 Basf Ag Process for the preparation of liquid crystalline mixtures
WO1996019920A1 (en) * 1994-12-27 1996-07-04 Pfizer Pharmaceuticals Inc. Compositions for treating nematode infections in trees
US6001981A (en) * 1996-06-13 1999-12-14 Dow Agrosciences Llc Synthetic modification of Spinosyn compounds
AU707949C (en) * 1996-07-30 2006-01-19 Merial, Inc. Anthelmintic formulations
AU4139797A (en) * 1997-06-09 1998-12-30 Nauchno-Proizvodstvennoye Obiedinenie "Farmbiomed" (streptomyces avermitilis) strain, method for separating avermectin complexe s and preparations for protecting plants and animals
RU2138268C1 (en) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Agent suppressing proliferation and causing death of tumor cells and protecting normal cells
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
GB9825402D0 (en) * 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
DE19913534A1 (en) * 1999-03-25 2000-10-05 Bayer Ag Avermectin derivatives
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
KR20020067781A (en) * 2001-02-19 2002-08-24 주식회사 엘지씨아이 Anthelmintic injectable composition containing ivermectin and process for preparation thereof
IL160619A0 (en) 2001-09-17 2004-07-25 Lilly Co Eli Pesticidal formulations pesticidal formulations
KR101135833B1 (en) 2004-03-02 2012-04-16 가부시키가이샤 아데카 Weakly basic hindered amines having carbonate skeletons, synthetic resin compositions, and coating compositions
US7312248B2 (en) 2004-09-23 2007-12-25 Schering-Plough Animal Health Corporation Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives
MX2007006072A (en) * 2004-11-19 2007-07-11 Schering Plough Ltd Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1h-pyrrol-2-yl) acrylonitrile derivatives.
MX2007015729A (en) * 2005-06-09 2008-02-21 Schering Plough Ltd Control of parasites in animals by n-[(phenyloxy)phenyl]-1,1,1-tr ifluoromethanesulfonamide and n-[(phenylsulfanyl)phenyl]-1,1,1-tr ifluoromethanesulfonamide derivatives.
US8119667B2 (en) * 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
EP1849363A1 (en) * 2006-03-09 2007-10-31 Cheminova A/S Synergistic combination of glutamate- and GABA-gated chloride agonist pesticide and at least one of Vitamin E or Niacin
US20070238700A1 (en) * 2006-04-10 2007-10-11 Winzenberg Kevin N N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites
WO2008076259A1 (en) * 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble prodrugs of florfenicol and its analogs
EP2102154A1 (en) * 2006-12-13 2009-09-23 Schering-Plough Ltd. Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof
KR100831643B1 (en) * 2007-04-10 2008-05-22 류충오 Connection joints and composite drive shaft assemblies with them
TWI430995B (en) 2007-06-26 2014-03-21 Du Pont Naphthalene isoxazoline invertebrate pest control agents
LT2957284T (en) 2007-06-27 2018-04-10 E. I. Du Pont De Nemours And Company Animal pest control method
TWI556741B (en) 2007-08-17 2016-11-11 英特威特國際股份有限公司 Isoxazoline compositions and their use as antiparasitics
TWI468407B (en) 2008-02-06 2015-01-11 Du Pont Mesoionic pesticides
CN102131772B (en) * 2008-07-30 2015-03-11 英特威国际有限公司 Process for the preparation of *oxazoline-protected aminodiol compounds used as intermediates of florfenicol
CN102282154B (en) 2008-12-04 2015-07-01 梅瑞尔公司 Dimeric avermectin and milbemycin derivatives
BRPI1008822B1 (en) 2009-02-16 2019-04-09 Zoetis Services Llc ANTI-PARASITY VETERINARY COMPOSITION AND USE
AR075846A1 (en) 2009-03-17 2011-04-27 Organon Nv FARMACO ADMINISTRATION SYSTEM OF LACTONA MACROCICLICA.USO. TREATMENT METHOD
UA107804C2 (en) 2009-08-05 2015-02-25 Du Pont Mixtures of pesticides mezoionnyh
UA110924C2 (en) 2009-08-05 2016-03-10 Е. І. Дю Пон Де Немур Енд Компані Mesoionic pesticides
BR112012002519A2 (en) 2009-08-05 2019-09-24 Du Pont "mesoionic pesticides"
WO2011017347A2 (en) 2009-08-05 2011-02-10 E. I. Du Pont De Nemours And Company Mesoionic pesticides
AU2010303741A1 (en) * 2009-10-07 2012-04-19 Zoetis W Llc Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
US20120196821A1 (en) 2009-10-19 2012-08-02 Roger Mervyn Sargent Method and formulation for the control of parasites
WO2011075592A1 (en) 2009-12-17 2011-06-23 Merial Limited Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
EP2576523B1 (en) 2010-05-27 2016-01-13 E. I. du Pont de Nemours and Company Crystalline form of 4-[5 - [3 -chloro-5 -(trifluoromethyl)phenyl] -4,5 -dihydro-5 -(trifluoromethyl)-3 - isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1- naphthalenecarboxamide
AR081970A1 (en) 2010-06-24 2012-10-31 Intervet Int Bv INJECTABLE FORMULATION OF A MACROCICLIC AND LEVAMISOL LACTONE, FORMULATION AND VETERINARY USE
WO2012087630A1 (en) 2010-12-20 2012-06-28 E.I. Du Pont De Nemours And Company Pyridine and pyrimidine compounds for controlling invertebrate
EP2785719B1 (en) 2011-12-02 2017-11-08 Merial, Inc. Long-acting injectable moxidectin formulations and novel moxidectin crystal forms
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
CN102872066B (en) * 2012-10-19 2014-07-02 厦门大学 Uses of ivermectin and its derivatives
EP2886640A1 (en) 2013-12-18 2015-06-24 Riga Technical University Process for isolation of milbemycins A3 and A4
KR101789736B1 (en) 2017-08-30 2017-10-25 대한민국 Composition containg ivermectin for Exterminating Clavinema mariae Infection
WO2022034226A1 (en) 2020-08-14 2022-02-17 Universidad De Navarra Avermectin and milbemycin compositions for inhalation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171314A (en) * 1977-12-19 1979-10-16 Merck & Co., Inc. 13-Halo and 13-deoxy C-076 compounds
JPS5953403A (en) * 1982-09-21 1984-03-28 Sankyo Co Ltd Miticidal composition
US5416084A (en) * 1992-08-14 1995-05-16 G.D. Searle & Co. Benzo-fused thiomorpholinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (en) * 1976-04-19 1984-07-16 Merck & Co Inc SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS
US4134973A (en) * 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
PH15982A (en) * 1977-10-03 1983-05-18 Merck & Co Inc Selective hydrogenation producta of c-076 compounds and derivatives thereof
PH16612A (en) * 1977-12-19 1983-11-28 Merck & Co Inc 13-halo and 13-deoxy derivatives of c-076 compounds
US4200581A (en) * 1978-08-04 1980-04-29 Merck & Co., Inc. Alkyl derivatives of C-076 compounds
US4429042A (en) * 1978-09-08 1984-01-31 Merck & Co., Inc. Strain of Streptomyces for producing antiparasitic compounds
US4328335A (en) * 1979-08-13 1982-05-04 Merck & Co., Inc. Process for the interconversion of C-076 compounds
US4285963A (en) * 1980-08-07 1981-08-25 Merck & Co., Inc. Novel derivatives of C-076 compounds
US4378353A (en) * 1981-02-17 1983-03-29 Merck & Co., Inc. Novel C-076 compounds
US4333925A (en) * 1981-05-11 1982-06-08 Merck & Co., Inc. Derivatives of C-076 compounds
JPS5878594A (en) * 1981-11-06 1983-05-12 Sankyo Co Ltd Preparation of antibiotic substance b-41d, e, and g
US4423209A (en) * 1982-02-26 1983-12-27 Merck & Co., Inc. Processes for the interconversion of avermectin compounds
US4427663A (en) * 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
US4423204A (en) * 1982-09-02 1983-12-27 The Upjohn Company Amorphous copolyamide from lactam, dicarboxylic acid and bisimidazoline
US4469682A (en) * 1983-01-28 1984-09-04 Merck & Co., Inc. Avermectin and milbemycin phosphate esters, pharmaceutical compositions, and method of use
GR852232B (en) * 1984-09-14 1986-01-14 American Cyanamid Co
HUT39739A (en) * 1984-12-04 1986-10-29 Ciba Geigy Ag Process for production of derivatives of 13,3-milbemycin and medical preparatives containing thereof
GB8502925D0 (en) * 1985-02-05 1985-03-06 Ici Plc Macrocyclic lactones
ES8802229A1 (en) * 1985-04-30 1988-04-16 Glaxo Group Ltd Macrolide antibiotics and their preparation
NZ216908A (en) * 1985-07-29 1989-06-28 Merck & Co Inc Avermectin derivatives
NZ217567A (en) * 1985-09-13 1988-07-28 Glaxo Group Ltd Avermectin/milbemycin derivatives
EP0235085A1 (en) * 1986-02-20 1987-09-02 Ciba-Geigy Ag 13-Beta-sugar derivatives of milbemycine, their preparation and use as ekto- and endo-parasitic agents for treatment of animals and plants
GB8606120D0 (en) * 1986-03-12 1986-04-16 Glaxo Group Ltd Process
US4831016A (en) * 1986-10-31 1989-05-16 Merck & Co., Inc. Reduced avermectin derivatives
GB8815967D0 (en) * 1988-07-05 1988-08-10 Pfizer Ltd Antiparasitic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171314A (en) * 1977-12-19 1979-10-16 Merck & Co., Inc. 13-Halo and 13-deoxy C-076 compounds
JPS5953403A (en) * 1982-09-21 1984-03-28 Sankyo Co Ltd Miticidal composition
US5416084A (en) * 1992-08-14 1995-05-16 G.D. Searle & Co. Benzo-fused thiomorpholinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Also Published As

Publication number Publication date
ES556466A0 (en) 1987-12-01
SU1560059A3 (en) 1990-04-23
CN1007266B (en) 1990-03-21
JPH0637501B2 (en) 1994-05-18
PL260806A1 (en) 1987-11-16
GR861965B (en) 1986-11-26
ES8800986A1 (en) 1987-12-01
OA08370A (en) 1988-02-29
YU134186A (en) 1987-12-31
JPS6229590A (en) 1987-02-07
DE3676396D1 (en) 1991-02-07
IE58640B1 (en) 1993-10-20
NO165881C (en) 1991-04-24
EP0214731A2 (en) 1987-03-18
NL950011I1 (en) 1995-12-01
PH23081A (en) 1989-04-10
IE861983L (en) 1987-01-27
AP8600040A0 (en) 1986-08-01
DK169036B1 (en) 1994-08-01
IL79523A (en) 1990-02-09
PT83070A (en) 1986-08-01
NO863014D0 (en) 1986-07-25
AU6056986A (en) 1987-05-14
LU88788I2 (en) 1996-11-05
EP0214731A3 (en) 1987-07-22
NO863014L (en) 1987-01-28
NL950011I2 (en) 1997-03-03
DK353486D0 (en) 1986-07-25
CY1719A (en) 1994-05-06
FI87367C (en) 1992-12-28
PL153429B1 (en) 1991-04-30
DK353486A (en) 1987-01-28
HK65793A (en) 1993-07-16
NO1995009I1 (en) 1995-11-17
FI863065A0 (en) 1986-07-25
NO165881B (en) 1991-01-14
PT83070B (en) 1989-02-28
HU195856B (en) 1988-07-28
EP0214731B1 (en) 1991-01-02
BG46601A3 (en) 1990-01-15
AU572402B2 (en) 1988-05-05
MA20746A1 (en) 1987-04-01
CA1339480C (en) 1997-09-30
YU44294B (en) 1990-04-30
FI87367B (en) 1992-09-15
US5089480A (en) 1992-02-18
US5451511A (en) 1995-09-19
UA6345A1 (en) 1994-12-29
SK278513B6 (en) 1997-08-06
HUT44081A (en) 1988-01-28
FI863065A7 (en) 1987-01-28
NZ216980A (en) 1988-10-28
CN86105218A (en) 1987-03-04

Similar Documents

Publication Publication Date Title
AP37A (en) Antiparasitic agents and process of their preparation.
EP0276131B1 (en) Non-natural demethylavermectins and process therefor
EP0284176B1 (en) Process for production of avermectins and cultures therefor
US5702924A (en) Process for preparing antiparasitic agents
EP0350187B1 (en) Antiparasitic agents
US4929638A (en) C.25 [substituted(2-propenyl)]milbemycins
DE69329821T2 (en) A STREPTOMYCES AVERMITILIS STRAG GLYCOSYLATES AVERMECTIN COMPOUNDS
US5840704A (en) Antiparasitic agents and process for their preparation
EP0674649B1 (en) Antiparasitic agents
KR890000405B1 (en) Preparation process for derivative of avermectin and milbemycun
US5312753A (en) Strain of streptomyces avermitilis capable of glycosylating avermectin compounds at the 13- and 14A positions
CA1340678C (en) Antiparasitic avermectin derivatives
CS262673B2 (en) Process for preparing new derivatives of avermectine